Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Fineline Cube Jan 20, 2026
Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Fineline Cube Jan 20, 2026
Company Drug

Laekna Therapeutics Initiates Phase III Trial for Breast Cancer Candidate LAE002 in Combination with Fulvestrant

Fineline Cube May 30, 2024

Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced the enrollment...

Company

Merck KGaA Launches Construction on Largest Asia-Pacific Investment with South Korean Bioprocessing Plant

Fineline Cube May 30, 2024

Merck KGaA (ETR: MRK), the German science and technology company, has commenced construction on a...

R&D

Shanghai Research Team Achieves Global First in Treating Type 2 Diabetes with Stem Cell Therapy

Fineline Cube May 30, 2024

A groundbreaking study out of Shanghai has made a significant stride in diabetes treatment. A...

Company Deals

Johnson & Johnson to Acquire Atopic Dermatitis Therapy NM26 in $1.25 Billion Deal

Fineline Cube May 30, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has entered into a definitive...

Company Drug

Jiangsu QYuns Therapeutics Initiates Phase III Trial for Skin Disease Candidate QX005N

Fineline Cube May 30, 2024

Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...

Company Deals

HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies

Fineline Cube May 30, 2024

HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into...

Company Drug

Wanbangde’s Huperzine A Earns Orphan Drug Status from FDA for Treating Neonatal Brain Injury

Fineline Cube May 30, 2024

Wanbangde New Building Materials Co., Ltd (SHE: 002082), a company operating in China, has announced...

Company Drug

Zelgen Biopharmaceuticals Gets NMPA Approval for Jacktinib Vitiligo Trial in Adolescents and Adults

Fineline Cube May 30, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has received...

Company Drug

Hengrui Pharmaceuticals’ Vitiligo Treatment SHR0302 and Diabetes Drug HRS9531 Get Green Light from China’s NMPA

Fineline Cube May 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading biopharmaceutical company based in China, has...

Company Deals

Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended

Fineline Cube May 30, 2024

Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co.,...

Company Drug

Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval

Fineline Cube May 30, 2024

Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...

Company Drug

Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC

Fineline Cube May 30, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Deals Medical Device

Jiangxi Rimag Group Sets IPO Price Range for Hong Kong Debut, Aims to Raise Up to USD 2.15 per Share

Fineline Cube May 30, 2024

Jiangxi Rimag Group Co., Ltd, a leading medical imaging services provider based in China, has...

Company Deals

IVD Medical Holding Ltd Enters Non-Binding MoU with Chinese Chemiluminescence IVD Company for Potential Collaboration

Fineline Cube May 30, 2024

IVD Medical Holding Ltd (HKG: 1931), a leading in vitro diagnostic (IVD) company based in...

Company Deals

BMS Strikes Deal with Prothena for Potential Disease-Modifying Neurology Drug PRX019

Fineline Cube May 30, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has executed an exclusive global licensing agreement with Prothena...

Company Medical Device

Sino Medical Sciences’ Innovative Drug-Coated Stent System Accepted for NMPA Review

Fineline Cube May 29, 2024

Sino Medical Sciences Technology Inc. (SHA: 688108), a China-based medical technology company, has announced that...

Company Deals

Gilead Partners with Cartography Biosciences to Develop Therapies for Triple-Negative Breast Cancer

Fineline Cube May 29, 2024

Gilead Sciences (NASDAQ: GILD) has entered into a collaboration agreement with Cartography Biosciences, a US-based...

Company Deals

Sanofi Partners with Bluecrux to Enhance Supply Chain with AI Technologies

Fineline Cube May 29, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with...

Company Deals

Bio-Thera Solutions Partners with STADA for European Commercialization of Golimumab Biosimilar

Fineline Cube May 29, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced a licensing...

Company Deals

Roche Extends Long-Standing Partnership with Hitachi High-Tech to Innovate Diagnostic Solutions

Fineline Cube May 29, 2024

Roche (SWX: RO), a major Swiss pharmaceutical company, has renewed its 46-year partnership with Japan’s...

Posts pagination

1 … 298 299 300 … 611

Recent updates

  • Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal
  • Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
  • AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly
  • Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus
  • Grand Pharmaceutical Files TLX591-CDx PSMA Diagnostic for Prostate Cancer in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Company Drug

Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study

Company Drug

AIM Vaccine’s PCV20 Gets NMPA Clinical Approval, Challenging Pfizer’s Monopoly

Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.